Singh Olga, Manukyan Hasmik, Tritama Erman, Lee Shwu-Maan, Weir Jerry P, Laassri Majid
Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Research and Development Division, PT. BioFarma, Bandung, West Java 40161, Indonesia.
Vaccines (Basel). 2025 Jan 15;13(1):75. doi: 10.3390/vaccines13010075.
BACKGROUND/OBJECTIVES: Conventional live oral poliovirus vaccines (OPVs) effectively prevent poliomyelitis. These vaccines are derived from three attenuated Sabin strains of poliovirus, which can revert within the first week of replication to a neurovirulent phenotype, leading to sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) among vaccinees and their contacts. A novel OPV2 vaccine (nOPV2) with enhanced genetic stability was developed recently; type 1 and type 3 nOPV strains were engineered using the nOPV2 genome as a backbone by replacing the capsid precursor polyprotein (P1) with that of Sabin strains type 1 and type 3, respectively. The nOPV vaccines have a high degree of sequence homology with the parental Sabin 2 genome, and some manufacturing facilities produce and store both Sabin OPV and nOPV. Therefore, detecting Sabin virus contaminations in nOPV lots is crucial.
This study describes the development of pan quantitative reverse transcription polymerase chain reaction (panRT-PCR) and multiplex one-step RT-PCR (mosRT-PCR) assays for the straightforward detection and identification of contaminating Sabin viruses when present in significantly higher amounts of nOPV strains.
The two assays exhibit high specificity, reproducibility, and sensitivity to detect 0.0001% and 0.00001% of Sabin viruses in nOPV, respectively. Additionally, an analysis of 12 trivalent nOPV formulation lots using both methods confirmed that the nOPV lots were free from Sabin virus contamination.
The results demonstrated that the RT-PCR assays are sensitive and specific. These assays are relevant for quality control and lot release of nOPV vaccines.
背景/目的:传统口服脊髓灰质炎减毒活疫苗(OPV)能有效预防脊髓灰质炎。这些疫苗源自脊髓灰质炎病毒的三种减毒萨宾株,在复制的第一周内可能回复为神经毒力表型,导致疫苗接种者及其接触者中散发性疫苗相关麻痹型脊髓灰质炎(VAPP)病例。最近研发出一种具有更高遗传稳定性的新型OPV2疫苗(nOPV2);1型和3型nOPV株分别以nOPV2基因组为骨架,通过用1型和3型萨宾株的衣壳前体多聚蛋白(P1)进行替换构建而成。nOPV疫苗与亲本萨宾2基因组具有高度序列同源性,一些生产设施同时生产和储存萨宾OPV和nOPV。因此,检测nOPV批次中的萨宾病毒污染至关重要。
本研究描述了用于直接检测和鉴定在大量nOPV株中存在的污染性萨宾病毒的全定量逆转录聚合酶链反应(panRT-PCR)和多重一步RT-PCR(mosRT-PCR)检测方法的开发。
这两种检测方法分别对检测nOPV中0.0001%和0.00001%的萨宾病毒具有高特异性、重现性和敏感性。此外,使用这两种方法对12个三价nOPV制剂批次进行分析,证实nOPV批次未受萨宾病毒污染。
结果表明RT-PCR检测方法灵敏且特异。这些检测方法适用于nOPV疫苗的质量控制和批放行。